Chemokine Therapeutics from ChemoCentryx
Interview with CEO, Thomas J. Schall, PhD, at JP Morgan Healthcare Conference
752 views
00:06:32 - Uploaded by Essinova on February 2, 2010
Essinova host BeiBei Song interviews Dr. Thomas J. Schall, Founder and CEO of ChemoCentryx Inc., during the 2010 JP Morgan Healthcare Conference in San Francisco.
ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered small molecule therapeutics that target the chemokine and chemo-attractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer.
Earlier in January, GlaxoSmithKline (GSK) exercised its option to obtain an exclusive license for further development and worldwide commercialization of ChemoCentryx' lead product candidate, Traficet-EN™ (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.
Tags: ChemoCentryx, Thomas Schall, chemokines, chemoattractants, chemokine receptors, gastrointestinal, inflammatory bowel disease, IBD, Crohn's disease, ulcerative colitis, Type 2 diabetes, rheumatoid arthritis, cancer, JP Morgan, Traficet-EN
COMMENTS
There are 0 comments. You must be logged in to comment.
Therapeutics & Vaccines
-
Vitae's Computationally-grown Molecules and Four Tough Diseases
-
Expanding Access to Patients in Need Around the World
-
Five Prime Therapeutics - Protein Medicines
-
Chemokine Therapeutics from ChemoCentryx
-
Developing RNAi Therapeutics (Part I)
-
Developing RNAi Therapeutics (Part II)
-
Developing RNAi Therapeutics (Part III)
